Abstract

Combining low‐dose tofacitinib with 308‐nm excimer may be an effective treatment for patients with nonsegmental vitiligo who were refractory to conventional therapies.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://dbpia.nl.go.kr/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
You do not currently have access to this article.